Champions Oncology Analyst Price Targets - Benzinga

Champions Oncology Inc

CSBRNASDAQ

Trade with Public

Trade with Public

$4.87

-0.0833-1.68%

最終更新: Oct 13, 10:24 AM

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Champions Oncology Analyst Price Targets - Benzinga

Champions Oncology Analyst Price Targets

Wall Street analyst price targets and consensus rating for Champions Oncology (CSBR).

Price Target Range — 3 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$12Upside to Avg. PT+146.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Mar 12, 2025	Craig-Hallum	Matt Hewitt	PT Raise	Buy	$8→$12
Dec 12, 2024	Craig-Hallum	Matt Hewitt	PT Raise	Buy	$6→$8
Sep 12, 2024	Craig-Hallum	Matt Hewitt	Upgrade	Hold→Buy	$6
Mar 13, 2024	Craig-Hallum	Matt Hewitt	Downgrade	Buy→Hold	—

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Craig-Hallum Maintains Buy on Champions Oncology, Raises Price Target to $12

Craig-Hallum analyst Matt Hewitt maintains Champions Oncology (NASDAQ:CSBR) with a Buy and raises the price target from $8 to $12.

Benzinga Newsdesk

PRO
Craig-Hallum Maintains Buy on Champions Oncology, Raises Price Target to $8

Craig-Hallum analyst Matt Hewitt maintains Champions Oncology (NASDAQ:CSBR) with a Buy and raises the price target from $6 to $8.

Benzinga Newsdesk

PRO
Craig-Hallum Upgrades Champions Oncology to Buy, Maintains Price Target to $6

Craig-Hallum analyst Matt Hewitt upgrades Champions Oncology (NASDAQ:CSBR) from Hold to Buy and maintains the price target from $6 to $6.

Benzinga Newsdesk

PRO
Craig-Hallum Downgrades Champions Oncology to Hold

Craig-Hallum analyst Matt Hewitt downgrades Champions Oncology (NASDAQ:CSBR) from Buy to Hold.

Benzinga Newsdesk

PRO
Roth MKM Maintains Buy on Champions Oncology, Lowers Price Target to $7.5

Roth MKM analyst Scott Henry maintains Champions Oncology (NASDAQ:CSBR) with a Buy and lowers the price target from $9 to $7.5.

Benzinga Newsdesk

PRO
Roth Capital Maintains Buy on Champions Oncology, Raises Price Target to $16

Roth Capital maintains Champions Oncology (NASDAQ:CSBR) with a Buy and raises the price target from $13.5 to $16.

Benzinga Newsdesk